SCHEMBL4277952

SCHEMBL4277952

CC(S)C(=O)Nc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.69
ALDH1A1 P00352 4/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
RXFP1 Q9HBX9 1/20 0.61
POLB P06746 1/20 0.57
GAA P10253 3/20 0.56
ATM Q13315 2/20 0.56
LMNA P02545 1/20 0.56
HSD17B10 Q99714 3/20 0.54
NAPRT Q6XQN6 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.53
HPGD P15428 3/20 0.53
HTT P42858 2/20 0.53
RAB9A P51151 2/20 0.53
HSP90AA1 P07900 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
TAAR1 Q96RJ0 1/20 0.53
GPR55 Q9Y2T6 1/20 0.53
MME P08473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13767783 1.00 MAPT (0.69) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL10458555 0.93 MAPT (0.74) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL24879174 0.89 TAAR1 (0.70) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL608889 0.83 POLB (0.61) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL9886 0.83 ALDH1A1 (0.85) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL18852431 0.83 ALDH1A1 (0.66) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL19425986 0.83 ALDH1A1 (0.85) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL11517284 0.82 MAPT (0.68) MAPTALDH1A1MEN1KMT2ARXFP1
SCHEMBL26502909 0.82 MAPT (1.00) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL6864880 0.81 ALDH1A1 (0.63) MAPTALDH1A1MEN1KMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242514-A1 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS CORCEPT THERAPEUTICS INCORPORATED 2023-08-03 US disclosed
US-11672800-B2 Combination therapies with EHMT2 inhibitors Epizyme, Inc. (US) 2023-06-13 US disclosed
US-20200054635-A1 COMBINATION THERAPIES WITH EHMT2 INHIBITORS Epizyme, Inc. 2020-02-20 US disclosed
US-10251392-B2 Antimicrobial devices and compositions AVENT, INC. (US) 2019-04-09 US disclosed
US-20090035342-A1 Antimicrobial Devices and Compositions AVANOS MEDICAL SALES, LLC 2009-02-05 US disclosed
EP-1781098-A2 ANTIMICROBIAL DEVICES AND COMPOSITIONS ACRYMED, INC. (US) 2007-05-09 EP disclosed
WO-2006015317-A2 ANTIMICROBIAL DEVICES AND COMPOSITIONS ACRYMED, INC. (US) 2006-02-09 WO disclosed
US-6610853-B1 N-(phenylsulfonyl)picolinamide derivatives, process for producing the same, and herbicide KUREHA KAGAKU KOGYO K.K. (JP) 2003-08-26 US disclosed
EP-1069112-A1 N-(PHENYLSULFONYL) PICOLINAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND HERBICIDE KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2001-01-17 EP disclosed
US-4399075-A Process for producing chlorinated phenoxytoluene derivatives ASAHI CHEMICAL COMPANY, LIMITED (JP) 1983-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10251392-B2 Antimicrobial devices and compositions AAAS, AOC1, COL14A1 MAPT 2314/4885ALDH1A1 178/4885MEN1 4622/4885
US-20090035342-A1 Antimicrobial Devices and Compositions AAAS, AOC1, COL14A1 MAPT 2314/4885ALDH1A1 178/4885MEN1 4622/4885
US-20230242514-A1 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, NR1I2 MAPT 4150/4885ALDH1A1 1007/4885MEN1 3088/4885
US-20200054635-A1 COMBINATION THERAPIES WITH EHMT2 INHIBITORS EHMT2, BHMT, SHMT2 MAPT 2065/4885ALDH1A1 430/4885MEN1 1229/4885
US-11672800-B2 Combination therapies with EHMT2 inhibitors EHMT2, BHMT, SHMT2 MAPT 2065/4885ALDH1A1 430/4885MEN1 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.